EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pluri Inc. (PLUR) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Pluri Inc. stock $0.89, price $1.12, that is 20.5% below the price, quality 14 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Israel

PI Pluri Inc. logo Thin data Nov 10, 2026

Pluri Inc.

PLUR · US
Expensive, weak quality

Our calculation puts a fair price 21% below what the stock costs today.

Mixed Growth (revenue 3y +52.4 %/yr in USD)
Negative equity (buybacks among others)
Insiders bought $1.3M (6M)
Revenue last quarter 16% below a year ago.
Fair value $0.8900 · Overvalued
Quality 14/100
Negative free cash flow
Trails peers (1/5)
Narrow moat 21/100 · thin data
Thin data
Estimate

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$26.08 $0.8500 Fair Value $0.8900 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.8500 – $26.08 · fair‑value band $0.6600 – $1.11 · the $1.12 price screens above the $0.8900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Pluri in your weekly email

Every Wednesday you see whether Pluri is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries.

Show moreShow less

The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform.

Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.

The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech.

It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Stock analysis

Pluri Inc. (PLUR) currently trades at $1.12, while our estimate is $0.8900, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.6600 (bear) to $1.11 (bull), the price of $1.12 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 14/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Pluri Inc. reported revenue of $1.0M in FY2026 versus $234K in FY2022, a compound +44.4%/yr. Reported net income was −$23.8M in FY2026.

Key figures

Market cap $14.5M Micro · P/S ratio 15.8 · EPS (TTM) $−2.44 · Return on equity −1,022% · Return on assets (EBIT) −65.7% (5-year average) · Operating margin −1,656% · Revenue (TTM) $1.0M · Revenue growth (YoY) −15.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −21%, PLUR screens richer than that median.

Fair Value

Bear $0.6600 Fair Value $0.8900 Bull $1.11
Price $1.12 · Downside -20.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 14/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 16
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $1.3M, on Oct 23, 2026.

  • BuyAlexandre Weinstein ManieuDirector, 10% owner833,334 shares at $1.50$1.3MOct 23, 2026

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 22/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−24.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.4%
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−128,156.5% (2020) → −2,454.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

PLUR screens overvalued: fair value 21% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pluri Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 14 · Bottom 25%
Fair Value upside −20.5% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −95.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −15.8% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 14.30× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PLUR
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PLUR
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PLUR
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PLUR
argenx SE ARGX $971.55 $908.40 −7% vs PLUR
CSL Limited CSL A$201.68 A$181.40 −10% vs PLUR
Moderna, Inc MRNA $250.83 $158.70 −37% vs PLUR
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PLUR
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PLUR
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PLUR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pluri Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pluri Inc. Fair Value". https://www.fairvalue-calculator.com/stock/PLUR

Frequently asked questions

Is Pluri Inc. (PLUR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.8900 versus a price of $1.12, about 21% lower (overvalued).
What is the fair value of PLUR?
Our estimate for Pluri Inc. is $0.8900 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.12.
What is the quality score of PLUR?
Pluri Inc. has a Quality Score of 14/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pluri Inc. (PLUR)?
Our calculated price target is the estimate of $0.8900 (as of Nov 10, 2026). Cautious scenario $0.6600, optimistic scenario $1.11. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pluri Inc. stock forecast for 2026?
Our estimate puts fair value at $0.8900, about 21% lower versus a price of $1.12 (overvalued). Cautious scenario $0.6600, optimistic scenario $1.11. The calculation is refreshed regularly with new filings.
What is the revenue of Pluri Inc. (PLUR)?
Pluri Inc. reported trailing-twelve-month revenue of about $1.0M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Pluri Inc. (PLUR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pluri Inc. it is $0.8900 per share (as of Nov 10, 2026), against a price of $1.12.
Is Pluri Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PLUR trades above its calculated fair value: price $1.12, fair value $0.8900, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PLUR?
No. The price is what the market pays today ($1.12); the fair value is what the company's own numbers justify ($0.8900). For Pluri Inc. the two are $0.2300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pluri Inc. worth?
The market values Pluri Inc. at about $14.5M (market capitalisation, as of Nov 10, 2026). Per share that is $1.12; our models calculate a fair value of $0.8900 per share.
What do the bullish and bearish scenarios say about PLUR?
Our models span a range for Pluri Inc.: cautious scenario $0.6600, base $0.8900, optimistic $1.11 per share (as of Nov 10, 2026, price $1.12). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pluri Inc. (PLUR)?
Balance-sheet figures for Pluri Inc. (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 14/100, which measures business quality independently of the share price.
How far is PLUR from its 52-week high?
Pluri Inc. trades at $1.12, about 75% below its 52-week high of $4.45 and 32% above the low of $0.8500 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8900 is for.
Which stocks are comparable to Pluri Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pluri Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $1.12, calculated fair value $0.8900 (−21%), Quality Score 14/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Pluri Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pluri Inc. (PLUR)?
The closing price on Nov 10, 2026 was $1.12. Our estimate is $0.8900, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pluri Inc. right now?
Weak quality (14/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pluri Inc.

How large is the market capitalisation of Pluri Inc. (PLUR)?
The market capitalisation of Pluri Inc. is $14.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pluri Inc. (PLUR)?
The price-to-sales ratio of Pluri Inc. is 15.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pluri Inc. (PLUR)?
Earnings per share at Pluri Inc. are $−2.44. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pluri Inc. (PLUR)?
The return on equity (ROE) of Pluri Inc. is −1,022% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pluri Inc. (PLUR)?
On an EBIT basis the return on assets of Pluri Inc. is −65.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pluri Inc. (PLUR)?
The operating margin of Pluri Inc. is −1,656% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pluri Inc. (PLUR)?
Revenue at Pluri Inc. is growing −15.8% versus a year earlier (3y avg +52.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pluri Inc. (PLUR) generate?
The free cash flow of Pluri Inc. is −$20.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pluri Inc. (PLUR) carry?
The net debt of Pluri Inc. is $31.4M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.